5/13/2025
Last update
5/13/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
USERS' SCORE
Moderately Good
Based on 16 Reviews
7.8
Supplement Facts
Serving Size: 1 Veggie Capsule
Serving Per Container: 60
Amount Per Serving
%DV
Vitamin K2 (from MenaQ7® Menaquinone, MK-7)
45 mcg
38%
Top Medical Research Studies
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
7
VKA treatment outcomes in atrial fibrillation
Our study involved a group of 1,350 patients with valvular and nonvalvular atrial fibrillation, all receiving vitamin K antagonists (VKAs). Over about 17 months, we noted an annual incidence of 4.4% for serious events like cardiovascular death and thromboembolic occurrences.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Most Useful Reviews
9
Platelet increase
50 people found this helpful
After taking calcium in a citrated form, I experienced profuse urination, which returned to normal after I stopped. Meanwhile, my platelets reduced, but since starting K-2, I have noticed a significant improvement, including stopping night awakenings. K-2 appears to reduce oxalates and helps prevent calcium from accumulating, which may be linked to my other issues. I will continue with this course.
7.5
Cleans blood vessels
17 people found this helpful
Vitamin K2-MK7 effectively controls blood clotting and cleans blood vessels of calcifications. It helps maintain brain activity while slowing the negative changes in the nervous system.
7.5
Stronger blood vessels
10 people found this helpful
Vitamin K2 is produced by the intestines, and those with poor microflora often have a deficiency. I was prescribed K2 to strengthen my blood vessels, and indeed, they feel stronger. After massage, I barely had any bruises. K2 is also essential for calcium absorption and bone strength. If this review helped, please like it.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
- All Researches
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
We aimed to find the best antithrombotic regimen for patients with atrial fibrillation (AF) who recently experienced acute coronary syndrome (ACS) or had a percutaneous coronary intervention (PCI).
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
User Reviews
USERS' SCORE
Moderately Good
Based on 16 Reviews
7.8
- All Reviews
- Positive Reviews
- Negative Reviews
9
Platelet increase
50 people found this helpful
After taking calcium in a citrated form, I experienced profuse urination, which returned to normal after I stopped. Meanwhile, my platelets reduced, but since starting K-2, I have noticed a significant improvement, including stopping night awakenings. K-2 appears to reduce oxalates and helps prevent calcium from accumulating, which may be linked to my other issues. I will continue with this course.
7.5
Cleans blood vessels
17 people found this helpful
Vitamin K2-MK7 effectively controls blood clotting and cleans blood vessels of calcifications. It helps maintain brain activity while slowing the negative changes in the nervous system.
7.5
Stronger blood vessels
10 people found this helpful
Vitamin K2 is produced by the intestines, and those with poor microflora often have a deficiency. I was prescribed K2 to strengthen my blood vessels, and indeed, they feel stronger. After massage, I barely had any bruises. K2 is also essential for calcium absorption and bone strength. If this review helped, please like it.
9
Calcium prevention
9 people found this helpful
An important supplement that prevents calcium from depositing in blood vessels. Without it, calcium poorly enters bones, accumulating in vessels and soft tissues. Vitamin K is known as a prescription drug for treating several chronic diseases, particularly respected in Japan for its medicinal properties.
9
Aids calcium absorption
8 people found this helpful
This is great for aiding calcium absorption and proper deposition. It has helped lower my blood calcium levels significantly.
Frequently Asked Questions
9
Joint pain relief
1 people found this helpful
I previously had a vitamin D deficiency that was remedied, yet I still suffered from bone and joint pain. After taking Dr. Best's vitamin K2 for two months, I found that the pain in my joints and bones disappeared. Vitamin K2 helps direct the calcium introduced by vitamin D into the bones. I recommend taking vitamin D with K2.
9
Platelet increase
50 people found this helpful
After taking calcium in a citrated form, I experienced profuse urination, which returned to normal after I stopped. Meanwhile, my platelets reduced, but since starting K-2, I have noticed a significant improvement, including stopping night awakenings. K-2 appears to reduce oxalates and helps prevent calcium from accumulating, which may be linked to my other issues. I will continue with this course.
9
Calcium absorption safety
1 people found this helpful
I faced a severe vitamin D3 deficiency, and my doctor prescribed a daily dosage of 5000 units. I learned that taking vitamin D3 in high doses without vitamin K2 can be dangerous for blood vessels. While vitamin D3 helps absorb calcium, it's vitamin K2 that ensures calcium reaches the bones instead of settling in blood vessels, which poses health risks. Always take them together to maintain health.
7.5
Stronger blood vessels
10 people found this helpful
Vitamin K2 is produced by the intestines, and those with poor microflora often have a deficiency. I was prescribed K2 to strengthen my blood vessels, and indeed, they feel stronger. After massage, I barely had any bruises. K2 is also essential for calcium absorption and bone strength. If this review helped, please like it.
9
Vascular health
1 people found this helpful
Vitamin K2 is essential if you’re taking vitamin D. It enhances calcium absorption but also lowers the risk of vascular calcification, which can lead to cardiovascular diseases. K2 directs calcium to the bones, decreasing the likelihood of osteoporosis and bone fractures. A daily dose of 45 mcg is sufficient when paired with 1000-2500 IU of vitamin D. I take it with a fat-containing breakfast since K2 is fat-soluble.
7.5
Improves blood rheology
1 people found this helpful
Vitamin K2, which is synthesised in the small intestine, can improve blood rheology if your blood is excessively liquid. It's also a necessary synergist for vitamin D3, as it directs calcium from the blood to the bones, preventing calcifications in vessels. If calcifications exist, a dose of 360 mcg should dissolve them. It's essential if you're taking vitamin D3 over 5000 IU.
8
Preventing vascular damage
5 people found this helpful
If you're taking calcium or vitamin D3 in high doses, you must supplement with vitamin K2 to keep blood vessels free of excess calcium. K2 transports calcium ions to bones, preventing fragility. Dr. Berg recommends natural vitamin K2 MK-7, which works well. It's tasteless, odourless, and has had no adverse effects for me.
6
Blood clot prevention
1 people found this helpful
For high doses of vitamin D (over 5000), I recommend ensuring calcium goes to the bones and not the blood vessels. MK7, at higher doses (200 mcg), enhances vessel elasticity without affecting blood clotting, preventing potential health issues like blood clots and kidney stones.
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
References
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. 10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. 10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. 10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. 10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. 10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. 10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. 10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. 10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. 10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. 10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. 10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. 10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. 10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. 10.1111/apt.18474
